母体遗传变异与非整倍体妊娠:叙述性综述
本叙述性综述系统检索了截至2026年1月12日的文献,纳入28项人类研究,总结了与非整倍体妊娠相关的母体遗传变异,并将其功能归类为减数分裂重组、纺锤体动力学、检查点执行和母体-合子转换。综述提出「非整倍体易感性」可作为不孕遗传诊断的机制驱动维度,并指出KIF18A、ELL3、CEP120的罕见可能致病变异及PLK4、CCDC66的常见变异证据质量较高。
要点
- 非整倍体妊娠与母体遗传变异相关,涉及减数分裂重组、纺锤体动力学等机制。
- KIF18A、ELL3、CEP120罕见变异及PLK4、CCDC66常见变异证据质量较高。
- 部分商业不孕NGS面板基因与非整倍体的直接关联仍需验证。
核心结论
- 母体遗传变异与非整倍体妊娠相关,支持「非整倍体易感性」作为不孕遗传诊断的新维度。
研究设计与样本
- 叙述性综述,系统检索PubMed、Embase和Cochrane Library(截至2026年1月12日),最终纳入28项人类研究。
主要发现
- 从28项研究中识别出与非整倍体妊娠相关的母体变异,功能上涉及减数分裂重组、纺锤体动力学、检查点执行和母体-合子转换。
- KIF18A、ELL3和CEP120的可能致病罕见变异,以及PLK4和CCDC66的常见变异,有较高质量证据支持。
- HFM1、MCM9、MEI1、BUB1B、NLRP2、NLRP7和TLE6等基因已纳入商业不孕NGS面板,但其与非整倍体的直接关联需进一步验证。
关键数值与推荐
- 罕见变异按ACMG/AMP指南分类,常见变异基于效应估计和功能验证评估。
- 研究质量采用改良Newcastle-Ottawa量表评价。
- 纳入标准要求遗传确认非整倍体(卵母细胞/胚胎/妊娠产物/胎儿细胞)及母体变异(罕见单核苷酸变异、SNP、≤50 bp小插入缺失)。
临床怎么用
- 对核型正常、不明原因不孕且反复非整倍体妊娠或不同周期生殖表型异质的女性,可考虑评估非整倍体易感性相关基因。
- 临床解读商业NGS面板中HFM1、MCM9、MEI1、BUB1B、NLRP2、NLRP7、TLE6等基因时,应注意其与非整倍体的直接关联尚未充分验证。
局限性
- 本综述为叙述性综述,未报告定量合并分析。
- 部分基因与非整倍体的直接关联仍需进一步验证。
- 需优先开展人工智能增强的临床-基因组关联研究并开发整合临床因素的多基因风险模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human aneuploid conception, a leading cause of infertility, pregnancy loss, and congenital disorders (e.g. Down's syndrome), arises from errors in chromosome segregation during oocyte meiosis or embryonic mitosis. While advanced maternal age is a well-established risk factor, significant inter-individual variation exists among younger women, suggesting a substantial role for maternal genetic determinants. OBJECTIVE AND RATIONALE: This review summarizes the identified maternal genetic variants associated with aneuploid conceptions and highlights directions for future research. SEARCH METHODS: We systematically searched PubMed, Embase, and the Cochrane Library (up to 12 January 2026), using key terms related to maternal genetics, genetic variants, aneuploidy, and pregnancy. Inclusion criteria were human studies, genetic confirmation of aneuploidy (in oocytes/embryos/products of conception/fetal cells), maternal variants (rare single-nucleotide variations, single-nucleotide polymorphisms, and small indels [≤50 bp]), and English-language publications. Exclusion criteria were non-human studies, structural/non-aneuploid numerical abnormalities, paternal factors, and conference abstracts. Extracted data items included study identifiers, population characteristics, variant details, detection methods, clinical phenotypes, type and origin of aneuploidy, pathogenicity or effect assessment, and gene inclusion in currently commercially available infertility next-generation sequencing (NGS) panels. Rare variants were classified per American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines, whereas common variants were evaluated based on effect estimates and functional validation. Study quality was appraised using a modified Newcastle-Ottawa Scale. Supplementary searches explored associations between the identified genes and a broader range of reproductive phenotypes. OUTCOMES: From 28 studies covering the broad clinical spectrum of aneuploid pregnancies (including embryo arrest, implantation failure, pregnancy loss, hydatidiform mole, and fetal aneuploidy), we identified maternal variants associated with aneuploid conceptions. These were functionally categorized into meiotic recombination, spindle dynamics, checkpoint enforcement, and the maternal-to-zygotic transition. Among them, variants in several genes are supported by higher-quality evidence, including likely pathogenic rare variants in KIF18A, ELL3, and CEP120, as well as common variants in PLK4 and CCDC66. Although some identified genes (HFM1, MCM9, MEI1, BUB1B, NLRP2, NLRP7, and TLE6) are included in commercial infertility NGS panels, their direct association with aneuploidy requires further validation. WIDER IMPLICATIONS: This review proposes that 'aneuploidy predisposition' constitutes a critical, mechanism-driven dimension for the genetic diagnosis of infertility, complementing phenotype-based frameworks. This approach would best serve women with unexplained infertility and a normal karyotype who have either a history of recurrent aneuploidy or heterogeneous reproductive phenotypes across different cycles. Adopting this perspective refines clinical genetic testing paradigms and underscores the need to prioritize artificial intelligence-enhanced clinico-genomic association studies and develop polygenic risk models integrated with clinical factors. PROSPERO REGISTRATION NUMBER: CRD42025636217.
引用
- Ha S, Liu W, Yuan P, et al. Maternal genetic variants associated with aneuploid conception: a narrative review. Hum Reprod Update. 2026. PMID: 42124334. doi:10.1093/humupd/dmag012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。